Login to Your Account



No Clash of the Titans

With Approvals Likely, Obesity Drugs Expected to Coexist

By Brian Orelli
BioWorld Insight Contributing Writer

Tuesday, May 29, 2012

After positive recommendations from the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) for both Vivus Inc.'s Qnexa (phentermine/topiramate) and Arena Pharmaceuticals Inc.'s lorcaserin, it looks like both drugs will get past the FDA on their second attempts.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription